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Table
Patients Characteristics and Outcomes by Diagnosis





Remission status Median (range) prior
regimens / N prior auto
Regimen intensity PFS
Follicular (n[ 13) 52 yrs (29-63) 1 (0-4) 5 CR, 5 PR, 3 SD 4 (2-8) / 3/13 (23%) 3 MA 10 NMA 3-yr: 62%
Diffuse large cell (n[ 13) 53 yrs (35-64) 2 (0-6) 8 CR, 4 PR, 1 SD 4 (1-7) / 3/13 (23%) 4 MA 9 NMA 3-yr: 23%
Mantle cell (n[ 5) 57 yrs (37-71) 2 (1-6) 5 CR 3 (2-4) / 4/5 (80%) 5 NMA 2 disease-free
(29-70 months)
Hodgkins (n[ 15) 35 yrs (20-50) 3 (0-5) 10 CR, 3 PR, 1 SD, 1 PD 4 (2-13) / 12/15 (80%) 8 MA 7 NMA 3-yr: 47%
T-cell rich B-cell NHL (n[ 1) 38 yrs 2 PR 7 / No auto 1 MA Died at 1.5 months
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Introduction: Deletion of TP53 genemapped to 17p13, which
can be identiﬁed by conventional cytogenetics or ﬂuorescent
in situ hybridization (FISH), is associated with poor outcome
in multiple myeloma (MM), even after the introduction of
novel agents and the use of high-dose chemotherapy and
autologous (auto) or allogeneic (allo) hematopoietic stem cell
transplantation (HCT). Here we report the outcomes ofTable
TP53 Grp CG
Median age, years (range) 58 (34-69) 58 (31-79)
Sex (M/F) 24/15 62/55






Diagnosis to HCT >12 months, % 46 42
Maintenance therapy, % 59 62
Figure. Progression free survival.patients (pts) with TP53 deletion (del) on FISH studies who
underwent an auto- or allo-HCT at our institution.
Methods: We identiﬁed 39 pts with MM who had TP53 del
on FISH studies prior to HCT at our institution between 2008
and 2014, and compared their outcomes to a matched con-
trol group (CG) (n¼117) without TP53 del who were treated
during the same time period. Matchingwas based on age and
response to the last therapy prior to HCT.
Results: Patient characteristics are summarized in the
attached Table. The ISS stage at diagnosis was available for 27
pts in the TP53 group (TP53 Grp), 52% of whom had stage III
disease. Most pts in the TP53 Grp had received a proteasome
inhibitor (PI) (95%) or an immune modulatory agent (IMiD)
(72%) prior to HCT. The response to last therapy was either
stable or progressive disease in 36% of patients in both
groups. The median follow-up intervals were 16 and 26
months (m) for the TP53 Grp and CG, respectively. The
median overall survival (OS) in the TP53 Grp was 21 m vs 57
m in the CG; 2-year OS in the TP53 Grp was 46% vs 86% in
the CG (both, P<0.001). Median progression-free survival
(PFS) in the TP53 Grp was 8.5 m vs 28 m in the CG; 2-year
PFS in the TP53 Grp was 18% vs 56% in the CG (both, P<
0.001) (Figure 1). Three of the ﬁve pts in the TP53 Grp who
received an allo-HCT relapsed post-HCT, and none died of
non-relapse causes. In the TP53 Grp, univariate analysis
identiﬁed a trend toward a higher risk of disease
progression in pts who underwent HCT with relapsed
disease (HR¼2.4, 95% CI 0.99-5.8, P¼0.053). Otherwise, age,
response prior to HCT, time from diagnosis to HCT, ISS stage,
allo vs auto HCT, conditioning regimen, cytogenetics, and
prior exposure to PI or IMiD were all non-signiﬁcant factors.
On multivariate analysis for the entire cohort, p53del
(HR¼3.2, 95% CI 1.9-5.3, P<0.001) and relapsed disease at
HCT (HR 2.2, 95% CI 1.3-3.6, P¼0.002) were independent
factors associated with a higher risk of early progression.
Conclusions: In the era of PI, IMiD, and HCT, TP53 del re-
mains a poor prognostic factor in MM. Relapsed disease at
the time of HCT was associated with a higher risk of pro-
gression. Novel approaches and perhaps early allogeneic HCT
require evaluation in this high-risk population.
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Introduction: HAPLO-HSCT is a therapeutic option for pa-
tients with high-risk hematologic neoplasms with the ad-
vantages of quick availability, easy programation and
logistics, and a committed donor. It has shown promising
results in patients diagnosed with relapsed or refractory
Hodgkin’s lymphoma (HL) at least comparable to allogeneic
transplant from siblings or unrelated donors (Burroughs LM
et al. Biol Blood Marrow Transplant 2008; 14:1279-1287).
Patients and Methods: We retrospectively evaluate the re-
sults of HAPLO-HSCT with IV Busulfan (BUX) based RIC reg-
imens (Fludarabine 30 mg/m2 x5 days (-6 to -2),
Cyclophosphamide14,5mg/kg x2 days (-6 to -5), BUX 3,2mg/
kg x 1 (BUX1) or 2 days (BUX2) on days -3 to -2) and GVHD
prophylaxis based on PT-CY (50 mg/kg on days +3 and +4)
and a calcineurin inhibitor plus mycophenolate from day +5
performed in GETH centers to patients diagnosed with
relapsed or refractory HL.
Results: From March 2009, 43 HAPLO-HSCT have been per-
formed in patients diagnosed with relapsed or refractory HL
in 11 GETH centers. Median age was 31 years (17-53), 67%
were males and all were in advanced phases of their disease,
after a median of 4 prior treatment lines (2-8). Autologous
HSCT was previously employed in 79%, and allogeneic HSCT
in 7%. Five patients (11.5%) have received more than 2 prior
transplants. Disease status at HAPLO-HSCT evaluated by PET
was complete remission in 14 (32%) and persistent disease in
29 (68%). Bone marrow was employed in 11 (26%) and pe-
ripheral blood in 32 (74%), without T-cell depletion in all
cases. The haploidentical donor was patient’s mother (20),
father (3), siblings (19) or daughter (1). The RIC regimens
employed were BUX1 in 14 (32.5%) and BUX2 in 29 patients
(67.5%). Median neutrophils engraftment was day +18 (13-
44) and platelets >20K was day +26 (13-150). Graft failure
with autologous reconstitution happened only in 1 patient
(2.5%). The day +100 cumulative incidence (CI) of non-
relapse mortality (NRM) was 7% (3/43) and 16% (7/43) at 1
year post-transplant. The day +100 CI of grade II-IV acute
GVHD was 43%, and grade III-IV was 14.5%. Chronic GVHD CI
was 26.5% at 1 year, being extensive in 6%. After a median
follow-up for survivors of 13 months (3-60), the event-free
survival (EFS) was 59.5% and overall survival (OS) was 84%.
The 1-year CI of relapse or progression was 25%. Factors
related with better 1-year EFS were CR prior to HAPLO-HSCT
(93% vs 45%; p¼0.017) and receiving less than 4 treatment
lines prior to HAPLO-HSCT (100% vs 51.5%; p¼0.018). No
signiﬁcant differences were seen when comparing BUX1
against BUX2 in terms of NRM, EFS or OS.
Conclusions: HAPLO-HSCT with PT-CY and BUX based RIC
conditioning in relapsed or refractory HL patients, renders
long-lasting remissions with acceptable toxicity and GVHD,Figure. Overall survival and relapse risk according to probtaining better results in those transplanted in CR and with
less than 4 treatment lines prior to HAPLO-HSCT.82
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Background: Despite high curative rates with upfront ther-
apy, 20-30% of patients (pts) with Hodgkin lymphoma (HL)
experience disease relapse. Survival is further diminished for
those who fail autologous stem cell transplantation (ASCT).
However a fraction of pts can still be salvagedwith allogeneic
hematopoietic cell transplantation (allo-HCT).
Methods: In this retrospective cohort study, we investigated
the prognostic signiﬁcance of FDG-PET (interpreted by both
standard and Deauville criteria) among 42 consecutive pa-
tients with relapsed/refractory (RR) HL undergoing allo-HCT
from 2004-2012. All FDG-PET scans were obtained within 4
weeks prior to allo-HCT. The study cohort included recipients
of non-myeloablative (NMA) conditioning consisting of ﬂu-
darabine 150-200 mg/m2, cyclophosphamide 50 mg/kg and
total body irradiation TBI 200 cGy followed by trans-
plantation of umbilical cord blood (n¼30; 71%), matched
related (n¼10; 24%) and unrelated (n¼2; 5%) donor grafts.
Results: The median age was 28 years (range, 6-59); 52%
were males. Median time from HL diagnosis to allo-HCT was
34.6 months (range, 13.3-228.6) and median follow up of pts
was 26.5 months (range, 0.8-97.1). Pts had received a median
of 4 lines (range, 3-9) of prior regimens with 83% failing
ASCT; only 13 pts (31%) had achieved PET-negative (neg) CR
prior to allografting. Blinded re-evaluation of all pre-HCT
FDG-PET scans using Deauville 5-point scale (i.e. PETD-pos if
Deauville>3) by independent nuclear medicine physicians
conﬁrmed all pre-existing PET-neg reports, but also reclas-
siﬁed 4 prior PET-pos scans as PETD-neg (kappa coef-
ﬁcient¼0.79 [95% CI, 0.61-0.98] for PETD vs. archived PET). All
17 PETD-neg pts had signiﬁcantly better 3-yr post-transplant
OS, PFS, and relapse rate as compared to PETD-pos pts (100%
vs. 51%; 76% vs. 17%; 24% vs. 65%, respectively; all p<0.01,
Figure). Three out of four reclassiﬁed PETD-neg pts remained
alive and in remission after a median follow up of 3.3 yearse-transplant FDG-PET status by Deauville criteria.
